Binge-Eating Disorder

Clinical picture

• Eating unusually fast, past the point of fullness, alone from embarrassment, and when not hungry, followed by disgust, guilt and depressed mood.
• Binges are typically unplanned, occur in the evening or at night, and involve calorie-dense palatable food; daytime grazing can blur episode boundaries.
• Roughly two-thirds of treatment-seeking patients have obesity, but BED occurs across the weight spectrum and is routinely missed at normal weight.
• A weight-cycling history of repeated diets, commercial weight-loss failures and bariatric consultations is common at first presentation.
• Shame and secrecy delay disclosure, and many patients present for metabolic complications rather than for the eating behavior itself.
• Purging, fasting and driven exercise are absent, which distinguishes binge-eating disorder from bulimia nervosa on history alone.

Criteria snapshot

• Binge episodes with loss of control must occur at least weekly for 3 months and be accompanied by marked distress about the bingeing itself.
• Episodes require at least three of five features: eating rapidly, eating to uncomfortable fullness, eating without hunger, eating alone, and later self-disgust.
• No regular compensatory behavior is present, and the diagnosis is not made exclusively during a course of bulimia nervosa or anorexia nervosa.
• Severity is graded by weekly binge episodes: mild 1-3, moderate 4-7, severe 8-13, and extreme at 14 or more, matching the bulimia thresholds.
• Obesity is not a mental disorder and is neither necessary nor sufficient; the diagnosis rests entirely on eating behavior and associated distress.

Neurobiology

• Heritability is estimated at 45-57%, and dopaminergic reward circuitry with altered striatal D2 availability parallels substance use models.
• Heightened ventral striatal and orbitofrontal response to food cues combined with reduced prefrontal inhibitory control drives loss of control.
• Leptin resistance, blunted postprandial GLP-1 and peptide YY signaling, and altered ghrelin dynamics weaken normal satiety termination.
• Opioid and endocannabinoid systems mediate hedonic liking of palatable food, the pathway targeted by naltrexone-bupropion in weight management.
• Physical sequelae mirror obesity: type 2 diabetes, dyslipidemia, hypertension, metabolic syndrome, obstructive sleep apnea and chronic joint pain.
• Chronic stress with elevated cortisol increases intake of palatable food, tying HPA axis activity directly to binge episode frequency.

Psychology

• The emotion regulation model holds that binges briefly reduce negative affect and then amplify shame, producing a self-perpetuating escape cycle.
• Dietary restraint and weight stigma provoke abstinence violation thinking, so rigid dieting reliably precipitates rather than prevents binge episodes.
• Overvaluation of shape and weight is present in about half of patients and predicts worse outcome, warranting explicit assessment at intake.
• Childhood adversity, weight-related teasing and food insecurity are common antecedents that shape reward-based coping with food.
• Trait impulsivity and reward sensitivity, especially food-specific reward drive, predict binge frequency better than general psychopathology does.

Differential & comorbidity

• Distinguish from bulimia nervosa with compensation, night eating syndrome with a circadian pattern, and grazing that lacks discrete loss of control.
• Rule out hypothalamic injury, Prader-Willi syndrome, Kleine-Levin syndrome, and hyperphagia induced by antipsychotics, mirtazapine or corticosteroids.
• Comorbidity is substantial: major depression near 45-50%, anxiety disorders 35-65%, substance use near 25%, plus ADHD and bipolar spectrum illness.
• Suicidal ideation is elevated independent of body weight, so screen for it even when the presenting complaint is framed as a weight problem.
• Check metabolic labs and sleep apnea symptoms and review bariatric surgery history, since untreated bingeing predicts poorer postsurgical outcome.

Pharmacologic treatment

• Lisdexamfetamine 50-70 mg/day is the only FDA-approved agent and substantially reduces binge days; monitor pulse, blood pressure and misuse risk.
• Avoid stimulants in cardiovascular disease, uncontrolled hypertension or active substance use disorder, and never prescribe them for weight loss alone.
• Topiramate 100-300 mg/day reduces both binge frequency and weight, but cognitive dulling, paresthesia and teratogenicity limit routine use.
• SSRIs such as fluoxetine 60 mg/day or sertraline modestly reduce binge frequency with little weight effect and help comorbid mood or anxiety.
• GLP-1 receptor agonists have no approved indication for BED; treat the eating disorder rather than assuming weight loss will resolve the behavior.

Psychotherapy

• CBT-E or disorder-specific CBT across 16-20 sessions produces binge abstinence in roughly 50-60% and carries the strongest evidence base.
• Guided self-help CBT delivered in 8-12 brief supported sessions is nearly as effective for less severe presentations and greatly expands access.
• IPT matches CBT at longer follow-up and is preferred when interpersonal deficits and low self-esteem dominate the case formulation.
• DBT skills groups reduce binge episodes by targeting emotion dysregulation, although long-term maintenance data are weaker than for CBT.
• Behavioral weight loss achieves more weight change but inferior binge outcomes, so treating the eating disorder first is generally preferred.

Adjunct options

• Care is almost always outpatient; higher levels of care are reserved for severe comorbid depression, suicidality or destabilized diabetes.
• Structured regular eating with three meals and two snacks interrupts the restriction-binge cycle far more reliably than caloric restriction does.
• Weight-neutral framing and active reduction of weight stigma in the clinical encounter improve engagement, disclosure and treatment retention.
• Track outcome with the EDE-Q, Binge Eating Scale, weekly binge logs and metabolic labs, plus vital signs when stimulants are prescribed.
• Coordinate with primary care, sleep medicine and bariatric teams, and ensure presurgical screening identifies and treats active binge eating.

Clinical pearls

• The most common eating disorder in the US, exceeding anorexia and bulimia combined.
• Prescribing a diet to a binge eater usually worsens bingeing; regularize eating first.
• Lisdexamfetamine treats binge episodes, not obesity, and is not a weight-loss drug.